Replimune Group Inc. (REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, has a regulatory catalyst to watch next month.
The company's lead investigational product, RP1 (vusolimogene odeparepvec), is an oncolytic therapy derived from a genetically engineered strain of the herpes simplex virus. RP1, in combination with Bristol Myers Squibb's checkpoint inhibitor Opdivo, is under investigation for advanced melanoma, with the FDA decision due on April 10, 2026.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.